

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method of treating a human patient suffering from an ocular allergy, comprising:

administering to said patient an ophthalmic composition ~~containing~~ comprising from about 0.01% to about 0.1% of a macrolide compound.

Claim 2 (Currently Amended): A method according to claim 1, wherein said ocular allergy is allergic conjunctivitis.

Claim 3 (Currently Amended): A method according to claim 1 or 2, wherein said composition ~~contains~~ comprises from about 0.03% to about 0.06% of said macrolide compound.

Claim 4 (Currently Amended): A method according to claim 3, wherein said ~~macrolide compound~~ ophthalmic composition ~~contains~~ comprises about 0.03% of said macrolide compound.

Claim 5 (Currently Amended): A method according to claim 1, wherein said macrolide compound is FK506.


Claim 6 (Currently Amended): A method according to claim 1, wherein said ophthalmic composition is an eye drop.

Claim 7 (Currently Amended): A method according to claim 6, wherein said eye drop further ~~contains~~ comprises polyvinyl alcohol.

Claim 8 (Currently Amended): A method according to claim 7, wherein said eye drop ~~contains~~ comprises about 0.03% of said macrolide compound.

Claim 9 (Original): A method according to claim 8, wherein said eye drop is administered from about one to about 4 times per day.

Claim 10 (Currently Amended): A method according to ~~any of claims 1 to 9~~ claim 1, wherein said macrolide compound is a compound having the following formula (I) or a pharmaceutically acceptable salt thereof:



wherein adjacent pairs of R^1 and R^2 , R^3 and R^4 , and R^5 and R^6 each independently

a) consist of two adjacent hydrogen atoms, wherein R^2 is optionally alkyl, or

b) form another bond optionally between carbon atoms binding with the members of said pairs;

R^7 is hydrogen atom, hydroxy, alkyloxy or protected hydroxy, or may form oxo with R^1 ;

R^8 and R^9 each independently show hydrogen atom or hydroxy;

R^{10} is hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl, alkenyl substituted by one or more hydroxy or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula $-\text{CH}_2\text{O}-$;

Y is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula $\text{N}-\text{NR}^{11}\text{R}^{12}$ or $\text{N}-\text{OR}^{13}$;


R^{11} and R^{12} each independently show hydrogen atom, alkyl, aryl or tosyl;

R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{22} and R^{23} each independently show hydrogen atom or alkyl;

R^{24} is an optionally substituted ring that may contain one or more hetero atom(s); and

n is 1 or 2.

Claim 11 (Original): A method according to claim 10, wherein said macrolide compound has the following structure:



Claim 12 (Currently Amended): An ophthalmic composition for treatment of ocular allergy ~~containing~~ comprising from about 0.01% to about 0.1% of a macrolide compound.

Claim 13 (Currently Amended): An ophthalmic composition according to claim 12, wherein said ocular allergy is allergic conjunctivitis.

Claim 14 (Currently Amended): An ophthalmic composition according to claim 12 or 13, comprising ~~which contains~~ from about 0.03% to about 0.06% of said macrolide compound.

Claim 15 (Currently Amended): An ophthalmic composition according to claim 14, comprising ~~which contains~~ about 0.03% of said macrolide compound.

Claim 16 (Currently Amended): An ophthalmic composition according to claim 12, wherein said macrolide compound is FK506.


Claim 17 (Currently Amended): An ophthalmic composition according to claim 12, which is an eye drop.

Claim 18 (Currently Amended): An ophthalmic composition according to claim 17, wherein said eye drop further ~~contains~~ comprises polyvinyl alcohol.

Claim 19 (Currently Amended): An ophthalmic composition according to claim 18, wherein said eye drop ~~contains~~ comprises about 0.03% of said macrolide compound.

Claim 20 (Original): An ophthalmic composition according to claim 19, wherein said eye drop is administered from about one to about 4 times per day.

Claim 21 (Currently Amended): An ophthalmic composition according to ~~any of~~ ~~claims 12 to 20~~ claim 12, wherein said macrolide compound is a compound having the following formula (I) or a pharmaceutically acceptable salt thereof:



wherein adjacent pairs of R^1 and R^2 , R^3 and R^4 , and R^5 and R^6 each independently

- consist of two adjacent hydrogen atoms, wherein R^2 is optionally alkyl, or
- form another bond optionally between carbon atoms binding with the members of said pairs;

R^7 is hydrogen atom, hydroxy, alkyloxy or protected hydroxy, or may form oxo with R^1 ;

R^8 and R^9 each independently show hydrogen atom or hydroxy;

R^{10} is hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl, alkenyl substituted by one or more hydroxy or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula $-\text{CH}_2\text{O}-$;

Y is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula $\text{N}-\text{NR}^{11}\text{R}^{12}$ or $\text{N}-\text{OR}^{13}$;

R^{11} and R^{12} each independently show hydrogen atom, alkyl, aryl or tosyl;

R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{22} and R^{23} each independently show hydrogen atom or alkyl;

R^{24} is an optionally substituted ring that may contain one or more hetero atom(s); and
n is 1 or 2.

Claims 22-33 (Canceled).

Claim 34 (Currently Amended): A commercial package comprising the ophthalmic composition of ~~any of claims 12 to 22~~ claim 12 and a written matter associated therewith, the written matter stating that the composition can or should be used for allergic conjunctivitis.